Ysios Capital
Ysios Capital is a Spanish life sciences venture capital firm founded in 2008 that provides private equity financing to early- and mid-stage biotech, medical device, and diagnostics companies across Europe and the United States, managing over €400M across three VC funds plus the InceptionBio company-creation fund.
- Company typePrivate
- Founded2008
- HeadquartersSan Sebastian, Spain
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Ysios Capital does
Ysios Capital Partners, S.G.E.I.C., S.A.U. is a Spanish life sciences venture capital firm founded in 2008 and headquartered in San Sebastián, with a second office in Barcelona. The firm provides private equity financing to early- and mid-stage biotechnology, medical device, diagnostics, and digital therapeutics companies developing therapies for indications with high unmet medical need, with portfolio companies located across Europe and the United States. Ysios manages over €400 million in assets across three venture capital funds, acts as investment advisor to the listed Telescope Biotech Fund managed by Andbank Wealth Management, and in March 2026 launched InceptionBio, a €100 million target-size fund focused on biotech company creation in Spain in partnership with CDTI.
The firm invests across the full life sciences value chain, from academic spin-offs (e.g., IRB Barcelona/ICREA spin-offs Inbiomotion and Ona Therapeutics) through clinical-stage and NASDAQ-listed companies (Aura Biosciences, Fusion Pharmaceuticals, KALA BIO, LAVA Therapeutics, Mineralys Therapeutics), with a portfolio of 42+ companies, 19 products brought to market, and over 70 products at clinical stage. Ysios has completed six NASDAQ exits and ten M&A transactions, including Takeda's acquisition of TiGenix (~€450M), Vifor Pharma's acquisition of Sanifit (€375M), and Qiagen's purchase of STAT-Diagnostica (€172M).
Revenue is generated through management fees on its three VC funds and the InceptionBio vehicle, plus investment advisory fees on the listed Telescope Biotech Fund, with potential carried interest participation through portfolio exits. The firm operates a proprietary Y-mpact impact measurement methodology with a public Y-Score assessment tool (1-5 stars across Innovation, Social, and Governance pillars), and is supported by the European Investment Fund (EIF), CDTI, and the European Union. Distribution is conducted through direct project submissions, direct investment with board representation, public-private co-investment via CDTI's SICC Innvierte program, and wealth-management distribution via Andbank.
Ysios Capital firmographics
Firmographics- Name
- Ysios Capital
- Legal name
- Ysios Capital Partners, S.G.E.I.C., S.A.U.
- Website
- http://www.ysioscapital.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ysios Capital is a Spanish life sciences venture capital firm founded in 2008 that provides private equity financing to early- and mid-stage biotech, medical device, and diagnostics companies across Europe and the United States, managing over €400M across three VC funds plus the InceptionBio company-creation fund.
- Ownership category
- akta.pro rank
Ysios Capital industry classification
Industry- Product category
- Life Sciences Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
- akta.pro secondary industry
- Late-Stage Venture Capital (Series C+) (FSANAAAC)
Keywords
Where Ysios Capital is headquartered
LocationHeadquarters
- HQ city
- San Sebastian
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
Ysios Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Fund Management Fees: Ysios Capital generates revenue through management fees on three venture capital funds with over €400 million in assets under management, plus investment advisory fees on the Telescope Biotech Fund (a listed biotech fund managed by Andbank Wealth Management). A new €100 million target-size fund (InceptionBio) was launched in March 2026, with first closing already completed via CDTI's SICC Innvierte program.
- Carried Interest / Fund Returns: As a venture capital firm, Ysios Capital participates in fund returns through exits in its portfolio companies. The firm has completed six NASDAQ exits and ten M&A transactions, including landmark deals such as Takeda's acquisition of Tigenix (approximately €450M), Qiagen's purchase of STAT-Diagnostica (€172M), and Vifor Pharma's acquisition of Sanifit (€375M).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Fund terms and management fees are not publicly disclosed |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels6 records
Ysios Capital product offering
Product offeringCore offering
Ysios Capital is a European life sciences venture capital firm that provides private equity financing to early- and mid-stage biotech companies developing novel therapies for indications with high unmet medical need. It manages over €400 million across three venture capital funds, supplements this with a €100M InceptionBio company-creation fund, and acts as investment advisor to the listed Telescope Biotech Fund managed by Andbank Wealth Management. The firm combines capital with scientific, financial and operational expertise, supported by a proprietary Y-mpact impact measurement methodology.
Product overview
Ysios Capital is a Spanish/European life sciences venture capital firm whose offering is a platform-plus-modules investment architecture rather than a single SaaS product: (a) the core product is its three venture capital funds providing private equity financing to early- and mid-stage life sciences companies, supplemented by the InceptionBio €100M company-creation fund launched in March 2026 and the Telescope Biotech Fund advisory mandate; (b) proprietary differentiated capabilities include the in-house Y-mpact / Y-Score impact measurement methodology and public Y-Score Test tool, and the Whistleblowing Channel compliance service operated under Spanish Act 2/2023; and (c) supporting infrastructure includes the Valuat-based investor portal at ysios.valuat.com for fund reporting. These offerings collectively span the full life sciences investment value chain — from company creation through clinical-stage development — and serve limited partners/investors, portfolio companies and internal compliance stakeholders.
Differentiator
Problem solved
Functional benefit
Brands
- Y-mpact: Ysios' proprietary in-house methodology to measure the impact of investment activity across Innovation, Social and Governance (ISG) pillars.
- Y-Score
- InceptionBio
Products and services
- InceptionBio fund New €100M target-size fund launched in March 2026 focused on biotech company creation and early-stage projects in Spain, co-led by Managing Partner Joan Perelló and Partner Arturo Urrios, with first closing via CDTI SICC Innvierte. Aims to create at least three new biotech companies in 2026 by working with universities, research centers and scientific entrepreneurs on technology transfer.
- Ysios Capital venture capital funds (three funds) Core private equity product providing financing to early- and mid-stage highly innovative life sciences companies developing therapies for indications with high unmet medical need. Manages over €400 million in assets across three venture capital funds and has invested in more than 40 biotech companies, achieving six NASDAQ exits and ten M&A transactions (Tigenix/Takeda ~€450M, STAT-Diagnostica/Qiagen €172M, Sanifit/Vifor €375M).
- Telescope Biotech Fund Listed biotech fund managed by Andbank Wealth Management for which Ysios Capital acts as investment advisor, complementing its direct venture capital investment strategy. Distributed via Andbank's wealth management platform.
- Y-mpact / Y-Score impact measurement In-house proprietary methodology that measures the impact of Ysios's investment activity across three pillars — Innovation, Social and Governance (ISG) — producing a Y-Score rated from 1 (low) to 5 (very high) stars per pillar and as a weighted overall score. Includes a public-facing Y-Score Test questionnaire accessible at ysioscapital.com/measure-your-y-score/.
- Whistleblowing Channel Internal reporting system implemented under Spanish Act 2/2023 (transposing EU Directive 2019/1937), enabling confidential and anonymous reporting of regulatory breaches, with Wen Wen Cheng (Head of Legal) appointed as Whistleblowing Channel Manager. Covers Ysios, its venture capital funds and managed closed-end collective investment schemes.
- Investor portal (Valuat) Secure online login portal at ysios.valuat.com that provides Ysios Capital investors with access to fund and portfolio reporting.
Companies that use Ysios Capital
Customer profileNamed customers29 records
Segments6 records
Ideal customer profiles3 records
Ysios Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Ysios Capital partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered flagship and core.
- MSD (Merck & Co., Inc.)flagshipClinical trial collaboration and supply agreement with Ysios portfolio company Adcendo ApS. MSD provides pembrolizumab (KEYTRUDA®) to be evaluated in combination with Adcendo's ADCE-T02 in a new Phase Ib study in patients with advanced solid tumors. Adcendo sponsors the trial. First patient dosing anticipated in 2H 2026.
- HJ HyupJincoreDistribution partnership with Ysios portfolio company Inbiomotion to offer the MAF Test® in South Korea. The MAF Test® will benefit an estimated 34,000 new breast cancer patients each year in South Korea. HJ HyupJin is a Seoul-based South Korean healthcare and precision diagnostics company.
- King's College London (Prof. Allan Young)coreResearch collaboration with Ysios portfolio company Synendos Therapeutics for the Phase 2 efficacy and safety clinical trial in patients with Generalized Anxiety Disorder (GAD). Professor Allan Young (Chair of Academic Psychiatry at Imperial College London) at King's College London leads the evaluation of Synendos' lead SERI molecule SYT-510. This is the first time a SERI molecule is dosed in a patient population.
- IRB BarcelonacoreYsios Capital works closely with IRB Barcelona (and ICREA) through multiple portfolio companies including Ona Therapeutics (spin-off of ICREA and IRB Barcelona, based at Barcelona Science Park) and Inbiomotion (spin-off of IRB Barcelona and ICREA, founded 2011 by Dr. Roger Gomis). InceptionBio fund also engages with research institutions to translate scientific discoveries into therapies.
- ICREA (Catalan Institution for Research and Advanced Studies)coreYsios Capital works closely with ICREA through multiple portfolio companies including Ona Therapeutics and Inbiomotion (both spin-offs of ICREA and IRB Barcelona). The InceptionBio fund aims to identify and develop new companies around scientific assets emerging from research institutions including ICREA-affiliated researchers.
- Andbank Wealth ManagementflagshipYsios Capital acts as investment advisor to the Telescope Biotech Fund, a listed biotech fund managed by Andbank Wealth Management (<https://andbank.es/boutiquehub/ysios/>). The partnership allows Ysios to provide investment advisory services to a publicly distributed fund product.
- Palex MedicalcoreDistribution partnership with Ysios portfolio company Inbiomotion for Spain and Portugal to distribute the MAF Test® diagnostic.
- Source BioSciencecoreDistribution partnership with Ysios portfolio company Inbiomotion for the United Kingdom and Ireland to distribute the MAF Test® diagnostic.
- SPA FarmacoreDistribution partnership with Ysios portfolio company Inbiomotion for Italy to distribute the MAF Test® diagnostic.
- The Scientific GroupcoreDistribution partnership with Ysios portfolio company Inbiomotion for Sub-Saharan Africa to distribute the MAF Test® diagnostic.
- BiocytogencoreAntibody agreement with Ysios portfolio company Ona Therapeutics to develop antibody-drug conjugates (ADCs) targeting solid tumors. Biocytogen granted Ona access to evaluate Biocytogen's proprietary RenMice®-derived fully human antibodies against a specific tumor target.
Scale indicators19 records
Recent moves7 records
Expansion highlights6 records
Ysios Capital competitors and assessment
Company assessmentDirect peers
- Forbion: Forbion is a leading European life sciences venture capital firm managing multiple funds and specializing in early- and late-stage biotech and medtech investments across therapeutic areas similar to Ysios's portfolio. Directly comparable in fund size (€2B+ AUM) and European biotech focus.
- Jeito Capital: Jeito Capital is a European life sciences VC firm investing in biotech and medtech companies across Europe and the US. Led the $75M Series C for Adcendo with Ysios as co-investor, demonstrating direct syndicate overlap and similar focus on therapeutics for high unmet medical need.
- Sofinnova Partners: Sofinnova Partners is one of Europe's oldest life sciences VC firms investing in therapeutics and medtech from early-stage through late-stage. Comparable geographic footprint, fund size, and therapeutic focus to Ysios Capital.
- Gilde Healthcare: Gilde Healthcare is a European healthcare and life sciences investor with dedicated biotech and medtech funds, participating in rounds alongside Ysios (e.g., Adcendo Series C). Similar mandate covering therapeutics, diagnostics and medical devices.
- HealthCap: HealthCap is a Nordic/European life sciences VC firm investing in late-stage biotech and medtech. Co-invested in Adcendo Series C with Ysios, with similar portfolio construction in clinical-stage therapeutics.
- Novo Holdings (Novo Seeds/Novo Ventures): Novo Holdings is a Danish life sciences investor operating venture arms (Novo Seeds, Novo Ventures) that invest in early- and late-stage biotech. Participated alongside Ysios in Adcendo Series C, and shares Danish biotech overlap (e.g., Adcendo, Cytoki Pharma).
- Asabys Partners: Asabys Partners is a Barcelona-based life sciences VC firm investing in therapeutics, medtech and digital health. Direct co-investor with Ysios in Ona Therapeutics and other Spanish/European biotech, with similar early-stage focus and Spanish ecosystem presence.
- Alta Life Sciences: Alta Life Sciences is a Spanish life sciences VC firm investing in early- to mid-stage biotech companies. Frequently co-invests with Ysios in portfolio companies (e.g., Ona Therapeutics) and shares the Spanish biotech focus.
- Columbus Venture Partners: Columbus Venture Partners is a Spanish venture capital firm specialized in life sciences and biotech. Co-led Ona Therapeutics' $86.6M Series B with Ysios participating, sharing Spanish/European biotech focus and stage mandate.
- Mérieux Equity Partners: Mérieux Equity Partners is a European PE/VC firm with a dedicated healthcare and life sciences strategy. Co-led Ona Therapeutics' $86.6M Series B with Ysios, with comparable European healthcare investment focus and stage range.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ysios Capital social profiles
Digital presenceYsios Capital compliance and trust
Trust signalCompliance3 records
Ysios Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ysios Capital leadership team
Management profileNumber of profiles
Profiles9 records
Ysios Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ysios Capital M&A and investment
M&A and investmentM&A
Investments80 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ysios Capital
What does Ysios Capital do?
Ysios Capital is a European life sciences venture capital firm that provides private equity financing to early- and mid-stage biotech companies developing novel therapies for indications with high unmet medical need. It manages over €400 million across three venture capital funds, supplements this with a €100M InceptionBio company-creation fund, and acts as investment advisor to the listed Telescope Biotech Fund managed by Andbank Wealth Management. The firm combines capital with scientific, financial and operational expertise, supported by a proprietary Y-mpact impact measurement methodology.
Is Ysios Capital a public or private company?
Ysios Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Ysios Capital founded?
Ysios Capital was founded in 2008. It employs 11 to 50 people.
Where is Ysios Capital based?
Ysios Capital is headquartered in San Sebastian, Spain, in the Europe region.
How does Ysios Capital make money?
Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest / Fund Returns.
Who are Ysios Capital's main competitors?
Direct peers on record are Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, HealthCap, Novo Holdings (Novo Seeds/Novo Ventures), Asabys Partners, Alta Life Sciences, Columbus Venture Partners and Mérieux Equity Partners.
Does Ysios Capital have an API?
No public API is recorded for Ysios Capital.
What industry is Ysios Capital in?
Ysios Capital's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAC, Late-Stage Venture Capital (Series C+). Its NAICS code is 523940 and its SIC code is 6282.